Quince Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $35.4M | $18.6M | $9.4M | $25.2M | $60.8M |
| Operating expenses | $58.1M | $57.3M | $34.6M | $52.0M | $90.3M |
| Operating income | -$58.1M | -$57.3M | -$34.6M | -$52.0M | -$90.3M |
| Pretax income | -$80.8M | -$56.7M | -$31.6M | -$51.9M | -$89.9M |
| Income tax expense | $3.2M | $87,000 | -$197,000 | -$284,000 | $0 |
| Net income | -$84.0M | -$56.8M | -$31.4M | -$51.7M | -$89.9M |
| Balance Sheet | |||||
| Cash and equivalents | $5.8M | $6.2M | — | — | — |
| Current assets | $22.9M | $44.0M | $77.4M | $93.7M | $111.7M |
| Total assets | $93.5M | $114.5M | $167.9M | $103.9M | $133.2M |
| Current liabilities | $43.2M | $7.3M | $9.6M | $3.1M | $14.2M |
| Total liabilities | $129.2M | $84.3M | $82.8M | $3.3M | $14.6M |
| Total debt | $11.8M | $10.4M | $11.1M | — | — |
| Stockholders' equity | -$35.7M | $30.1M | $85.1M | $100.6M | $118.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$41.4M | -$31.9M | -$18.3M | -$44.0M | -$62.9M |
| Depreciation and amortization | $100,000 | $200,000 | $300,000 | $200,000 | $344,000 |
| Stock-based compensation | $5.1M | $4.7M | $5.2M | $16.6M | $29.9M |
| Capital expenditure | $352,000 | $257,000 | $160,000 | $133,000 | $180,000 |
| Free cash flow | -$41.8M | -$32.2M | -$18.5M | -$44.2M | -$63.1M |
| Impairments | $0 | $0 | $0 | $825,000 | $0 |
Shares outstanding 16.3M · Free float 44.5%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.